Merck & Co., Inc. Furnishes Fourth-Quarter and Full-Year 2025 Financial Results
Summary
Merck & Co., Inc. announced its fourth-quarter and full-year 2025 financial results on February 3, 2026, via Ex. 99.1 press release. Fourth-quarter worldwide sales were $16.4 billion, representing 5% growth, with GAAP EPS of $1.19 and Non-GAAP EPS of $2.04. Full-year worldwide sales reached $65.0 billion, a 1% increase, with GAAP EPS of $7.28 and Non-GAAP EPS of $8.98. * KEYTRUDA/KEYTRUDA QLEX sales grew 7% to $31.7 billion. * WINREVAIR sales were $1.4 billion and CAPVAXIVE sales were $759 million. * GARDASIL/GARDASIL 9 sales declined 39% to $5.2 billion. * Animal Health sales grew 8% to $6.4 billion.
Why It Matters
Investors should note Merck & Co., Inc.'s Q4 worldwide sales growth of 5% to $16.4 billion and full-year sales of $65.0 billion, as detailed in Ex. 99.1. The strong performance in Oncology (KEYTRUDA up 7%) and Animal Health, alongside increasing contributions from WINREVAIR and CAPVAXIVE, signals key growth drivers. However, the 39% decline in GARDASIL/GARDASIL 9 sales is a material headwind.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how MRK traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View MRK Charts on TradingViewAffiliate link
Is this filing part of a pattern?
One disclosure is noise. Get a structured briefing covering 12 months of SEC filings, disclosure signals, and what to watch next.
Filing Details
Reported Items
Additional Information
- CIK Number
- 0000310158
- Filing Date
- Tuesday, February 3, 2026
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- positive